Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

被引:25
作者
Brefel, C
Thalamas, C
Rayet, S
Lopez-Gil, A
Fitzpatrick, K
Bullman, S
Citerone, DR
Taylor, AC
Montastruc, JL
Rascol, O
机构
[1] Fac Med Toulouse, INSERM, U455, Serv Pharmacol Med & Clin, F-31073 Toulouse, France
[2] Fac Med Toulouse, INSERM, U317, F-31073 Toulouse, France
[3] Hop Purpan, Ctr Invest Clin, F-31059 Toulouse, France
[4] SmithKline Beecham Pharmaceut, Clin Pharmacol Unit, Harlow CM19 5AW, Essex, England
[5] SmithKline Beecham Pharmaceut, Drug Metab & Pharmacokinet, Welwyn Garden City AL6 9AR, Herts, England
关键词
dopaminergic agonist; ropinirole; pharmacokinetics; food interaction; Parkinson's disease;
D O I
10.1046/j.1365-2125.1998.t01-1-00704.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Ropinirole is a specific non-ergoline dopamine D-2-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food. Methods This was an open, randomized, two sessions cross over study in 12 patients with Parkinson's disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: 'fasted' and 'fed'. Results The mean C-max was lower in the 'fed' regimen than in the 'fasted' one (-25%, P=0.002). The median t(max) was observed 2.6 h later in the 'fed' regimen than in the 'fasted' regimen (P<0.05). There was a slight but significant decrease in AUC(0,8 h) in the 'fed' regimen (P=0.03). Conclusions Food decreases the fate of absorption of ropinirole, but has little effect on the extent of absorption.
引用
收藏
页码:412 / 415
页数:4
相关论文
共 14 条